The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study.

Ozelo, Margareth C; Hermans, Cedric; Carcao, Manuel; Guillet, Benoît; Gu, Joan; Guerra, Randy; Tang, Leilei; Khair, Kate.

Afiliação

Ozelo MC; Hemocentro UNICAMP, University of Campinas, Campinas, São Paulo, Brazil.
Hermans C; St-Luc University Hospital, Université catholique de Louvain, Louvain, Belgium.
Carcao M; Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Guillet B; Haemophilia Treatment Center, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.
Gu J; Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Guerra R; Takeda Development Center Americas, Inc., 500 Kendal Street, Cambridge, MA 02142, USA.
Tang L; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Khair K; Haemnet, London, UK.

Ther Adv Hematol ; 15: 20406207231218624, 2024.

Article em En | MEDLINE | ID: mdl-38371314